Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 151 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Mikhailidis, Dimitri P [Clear All Filters]
Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial..
J Hepatol. 57(2), 476.
(2012). Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism..
Expert Opin Pharmacother. 9(4), 509-15.
(2008). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012). Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?.
Curr Med Res Opin. 26(4), 839-42.
(2010). Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly..
Atherosclerosis. 238(2), 182-4.
(2015). Statin-fibrate combination for mixed dyslipidaemia: a limited option?.
Curr Med Res Opin. 26(9), 2137-40.
(2010). Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients..
Open Cardiovasc Med J. 1, 8-14.
(2007). Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention..
Curr Vasc Pharmacol. 7(3), 264-6.
(2009). Statins and heart failure..
J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
(2010). Statins and nonalcoholic fatty liver disease: a bright future?.
Expert Opin Investig Drugs. 22(9), 1089-93.
(2013). Statins and non-alcoholic steatohepatitis..
J Hepatol. 64(1), 241-2.
(2016). Statins and regression of coronary atherosclerosis..
JAMA. 297(20), 2197; author reply 2197.
(2007). Statins and renal function. Is the compound and dose making a difference?.
Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
(2007). Statins and Type 2 Diabetes Mellitus: An Update After 1 Year..
Curr Pharm Des. 22(18), 2723-5.
(2016). Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?.
Expert Opin Pharmacother. 16(10), 1449-61.
(2015). Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures..
Curr Drug Targets. 8(8), 942-51.
(2007). Subclinical Cushing's syndrome and cardiovascular disease..
Lancet Diabetes Endocrinol. 2(5), 361.
(2014). Targeting vascular risk in patients with metabolic syndrome but without diabetes..
Metabolism. 54(8), 1065-74.
(2005). Therapeutic options for statin-intolerant patients..
Curr Med Res Opin. 28(3), 345-9.
(2012). Therapy: Caloric and fat intake in statin users..
Nat Rev Endocrinol. 10(8), 450-1.
(2014). Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?.
Arch Med Sci. 7(6), 1067-75.
(2011). To switch (statins) or not to switch? That is the question..
Expert Opin Pharmacother. 11(18), 2943-6.
(2010). Triglycerides and vascular risk: insights from epidemiological data and interventional studies..
Curr Drug Targets. 10(4), 320-7.
(2009). Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors..
J Diabetes Complications. 28(2), 122-3.
(2014).
(2017).